CYCC Cyclacel Pharmaceuticals Inc.

0.73
+0.01  (+1%)
Previous Close 0.72
Open 0.73
Price To Book 0.9
Market Cap 12,562,861
Shares 17,199,974
Volume 58,149
Short Ratio
Av. Daily Volume 309,630
Stock charts supplied by TradingView

NewsSee all news

  1. Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020

    – Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors and CYC065-venetoclax combination in AML/MDS and CLL dose escalation studies – BERKELEY HEIGHTS, N.J., Jan. 13, 2020 (GLOBE

  2. Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco

    BERKELEY HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

  3. Cyclacel's CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias

    BERKELEY HEIGHTS, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

  4. Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results

    – Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent – – Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel

  5. Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results

    BERKELEY HEIGHTS, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Noted mid-Dec 2014 that interim analysis suggests that trial will fail. Top-line data released February 23, 2017 that primary endpoint was not met. Complete remission (CR) improvement noted - secondary endpoint.
Sapacitabine (SEAMLESS)
Acute myeloid leukemia - cancer
Phase 1 updated data due 2020.
CYC065
Advanced cancers
Phase 1 initial proof of concept data due 2020.
CYC065 + venetoclax
Chronic lymphocytic leukemia (CLL)
Phase 1b/2 initial data due 2020.
Sapacitabine in combination with olaparib
BRCA mutant breast cancer
Phase 1 initial data due 2020.
CYC140
Leukemias
Phase 1 data at AACR April 1, 2019. 2/20 partial responses (PRs).
Sapacitabine and seliciclib
BRCA mutant breast cancer
Phase 1/2 data due 2020.
Sapacitabine and Venetoclax
Relapsed or refractory Acute myeloid leukemia or myelodysplastic syndrome (MDS)

Latest News

  1. Cyclacel Pharmaceuticals Reviews 2019 Achievements and Announces Key Business Objectives for 2020

    – Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors and CYC065-venetoclax combination in AML/MDS and CLL dose escalation studies – BERKELEY HEIGHTS, N.J., Jan. 13, 2020 (GLOBE

  2. Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2020 in San Francisco

    BERKELEY HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

  3. Cyclacel's CYC065 and Venetoclax Demonstrate Therapeutic Potential and Anticancer Activity in Acute Myeloid and Chronic Lymphocytic Leukemias

    BERKELEY HEIGHTS, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

  4. Cyclacel Pharmaceuticals Reports Third Quarter 2019 Financial Results

    – Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent – – Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel

  5. Cyclacel Pharmaceuticals to Release Third Quarter 2019 Financial Results

    BERKELEY HEIGHTS, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

  6. Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting

    BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

  7. Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    BERKELEY HEIGHTS, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative

  8. Cyclacel Pharmaceuticals Announces First Patient Treated With Oral CYC065 in a Phase 1 Study in Patients With Advanced Solid Tumors

    BERKELEY HEIGHTS, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative

  9. Cyclacel Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    BERKELEY HEIGHTS, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative